Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis

doi:10.5501/wjv.v13.i1.88660

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2670)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

WORD

HTML

1205

Figures (1-2)

207

Tables (1-2)

224

Sum=1710

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

148

Download

329

Sum=477

Publishing Process of This Article

Item

Count

Browse

135

Download

284

Sum=419

Mar 25, 2024 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Virol. Mar 25, 2024; 13(1): 88660
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.88660

Open in New Tab Full Size Figure Download Figure

Figure 1 PRISMA flow diagram of study selection process.

Open in New Tab Full Size Figure Download Figure

Figure 2 Forest plot analysis. A: Forest plot analysis for the outcome of mortality rate of bamlanivimab vs standard of care/placebo (SOC/PBO) in patients with coronavirus disease 2019 (COVID-19); B: Forest plot analysis for the outcome of hospitalization rate of bamlanivimab vs SOC/PBO in patients with COVID-19; C: Forest plot analysis for the outcome of emergency department visit of bamlanivimab vs SOC/PBO in patients with COVID-19; D: Forest plot analysis for the outcome of intensive care unit admission of bamlanivimab vs SOC/PBO in patients with COVID-19; E: Forest plot analysis for the outcome of adverse events of bamlanivimab vs SOC/PBO in patients with COVID-19. CI: Confidence interval.

Citation: Amani B, Khodavirdilou L, Rajabkhah K, Kardan Moghaddam V, Akbarzadeh A, Amani B. Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis. World J Virol 2024; 13(1): 88660
URL: https://www.wjgnet.com/2220-3249/full/v13/i1/88660.htm
DOI: https://dx.doi.org/10.5501/wjv.v13.i1.88660